Alitretinoin drug data and news

---

(PZ) Basilea Pharmaceutica Ltd. Reports 2005 Financial Results  Feb 27, 2006
...announced positive phase II trial results on our novel broad-spectrum antifungal drug BAL8557 and our international phase III alitretinoin registration trial ... - Houston Chronicle,

Basilea announces positive phase III results for ceftobiprole, its ...  Mar 2, 2006
About Alitretinoin (BAL4079) Alitretinoin is a novel vitamin A analog that is developed for patients with chronic hand eczema that is refractory to ... - PharmaLive.com (press release),

Basilea Pharmaceutica Ltd. Reports its Interim Results  Aug 23, 2005
The increase in R&D spending resulted primarily from progress in late stage development of Alitretinoin (BAL4079) for the treatment of chronic refractory hand ... - PrimeZone (press release),

Ordinary General Meeting of Shareholders of Basilea Pharmaceutica ...  Apr 12, 2005
BAL5788) into phase III in complicated skin and skin structure infections and hospital acquired pneumonia; the entry of alitretinoin (BAL4079) for severe ... - ArriveNet

Basilea's First-in-Class Antibiotic BAL5788 (Ceftobiprole) Moves ...  Apr 7, 2005
...including the entry of ceftobiprole (BAL5788) into phase III in complicated skin and skin structure infections; the entry of alitretinoin (BAL4079) for severe ... - ArriveNet,

Basilea Announces 2004 Financial Results Reflecting Successful ...  Mar 9, 2005
Basilea commenced its alitretinoin phase III program in severe chronic hand dermatitis refractory to topical treatment -- October 2004. ... - PrimeZone (press release),

Basilea Investigates Novel Antibiotic Class with Potential to ...  Mar 7, 2005
...months, Basilea also announced three additional major company milestones including entry of ceftobiprole into phase III, entry of alitretinoin (BAL4079) in ... - PrimeZone (press release),

Patients who are applying Panretin® gel should not concurrently use products that contain DEET (N, N-diethyl-m-toluamide), a common component of insect repellent products. Animal toxicology studies showed increased DEET toxicity when DEET was included as proof of the formulation. Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic antiretroviral agents, including protease inhibitors, macrolide antibiotics, and azole antifungals, the effect of Panretin® gel on the steady-state concentrations of these drugs is not known. No drug interaction data are available on concomitant administration of Panretin® gel and systemic anti-KS agents.